Predicting healthcare utilization using a pharmacy-based metric with the WHO's anatomic therapeutic chemical algorithm

Medical Care

Volumn 49, Issue 11, 2011, Pages 1031-1039

  Kuo, Raymond N ^a   Dong, Yaa Hui ^b   Liu, Jen Pei ^b,c   Chang, Chia Hsuin ^a   Shau, Wen Yi ^d   Lai, Mei Shu ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d Center for Drug Evaluation   (Taiwan)

Author keywords

claims data; comorbidity; drug utilization; health care costs; risk adjustment; utilization

Indexed keywords

ADOLESCENT; ADULT; AGED; ALGORITHM; ANATOMICAL THERAPEUTIC CHEMICAL ALGORITHM; ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL CHEMISTRY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH VISITOR; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; NEWBORN; OUTPATIENT; PHARMACY; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TAIWAN; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; ALGORITHMS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; DRUG THERAPY; FEMALE; HUMANS; INFANT; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PHARMACY; TAIWAN; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 80054963459     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31822ebe11     Document Type: Article

References (49)

1. Shwartz M, Iezzoni LI, Moskowitz MA, et al. The importance of comorbidities in explaining differences in patient costs. Med Care. 1996;34:767-782. (Pubitemid 126433270)
2. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic co-morbidity in longitudinal-studies-development and validation. J Chronic Dis. 1987;40:373-383. (Pubitemid 17055592)
3. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-cm administrative databases. J Clin Epidemiol. 1992;45:613-619.
4. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27. (Pubitemid 128456396)
5. Ash AS, Ellis RP, Pope GC, et al. Using diagnoses to describe populations and predict costs. Health Care Finan Rev. 2000;21:7-28.
6. Pope GC, Kautter J, Ellis RP, et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Finan Rev. 2004;25:119-141. (Pubitemid 39201560)
7. Zhao Y, Ash AS, Ellis RP, et al. Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med Care. 2005;43:34-43. (Pubitemid 40137612)
8. Perkins AJ, Kroenke K, Unutzer J, et al. Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol. 2004;57:1040-1048. (Pubitemid 39446643)
9. Gilmer T, Kronick R, Fishman P, et al. The medicaid R-x model-Pharmacy-based risk adjustment for public programs. Med Care. 2001;39:1188-1202. (Pubitemid 33603664)
10. Malone DC, Billups SJ, Valuck RJ, et al. Development of a chronic disease indicator score using a veterans affairs medical center medication database. J Clin Epidemiol. 1999;52:551-557. (Pubitemid 29281674)
11. Ghali WA, Quan H, Brant R. Risk adjustment using administrative data-impact of a diagnosis-type indicator. J Gen Intern Med. 2001;16:519-524. (Pubitemid 34203390)
12. Tucker A, Weiner J, Abrams C. Health-based risk adjustment: application to premium development and profiling. In: Wrightson CW, ed. Financial Strategy for Managed Care Organizations: Rate Setting, Risk Adjustment, and Competitive Advantage. Chicago, Ill: Health Administration Press; 2002:165-225.
13. Pine M, Jordan HS, Elixhauser A, et al. Modifying ICD-9-CM coding of secondary diagnoses to improve risk-adjustment of inpatient mortality rates. Med Decis Mak. 2009;29:69-81.
14. George J, Vuong T, Bailey MJ, et al. Development and validation of the medication-based disease burden index. Ann Pharmacother. 2006; 40:645-650.
15. Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data-the RxRisk model. Med Care. 2003;41:84-99.
16. Vonkorff M, Wagner EH, Saunders KA. Chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
17. Clark DO, Vonkorff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care. 1995;33:783-795.
18. Fishman PA, Shay DK. Development and estimation of a pediatric chronic disease score using automated pharmacy data. Med Care. 1999;37:874-883.
19. Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V-A VA-adapted pharmacy-based case-mix instrument. Med Care. 2003;41:761-774.
20. Lamers LM, van Vliet RCJA. The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. Health Policy. 2004;68:113-121. (Pubitemid 38373615)
21. Stam PJA, van Vliet RCJA, van de Ven WPMM. Diagnostic, pharmacybased, and self-reported health measures in risk equalization models. Med Care. 2010;48:448-457.
22. Prinsze FJ, van Vliet RCJA. Health-based risk adjustment: Improving the pharmacy-based cost group model by adding diagnostic cost groups. Inquiry-the Journal of Health Care Organization Provision and Financing. 2007;44:469-480. (Pubitemid 351287215)
23. The WHO Collaborating Centre for Drug Statistics Methodology. About the ATC/DDD system. 2009. Available at: http://www.whocc.no/atcddd/.
24. The National Health Research Institutes N. Introduction to the National Health Insurance Research Database (NHIRD), Taiwan. 2009. Available at: http://w3.nhri.org.tw/nhird/date-01.html. Accessed Aug 7, 2009.
25. Iezzoni LI. Risk Adjustment for Measuring Health Care Outcomes. Chicago: Health Administration Press; 2003.
26. Putnam KG, Buist DSM, Fishman P, et al. Chronic disease score as a predictor of hospitalization. Epidemiology. 2002;13:340-346. (Pubitemid 34415856)
27. Yamashiro Y, Shimizu T, Oguchi S, et al. The estimated incidence of cystic fibrosis in Japan. J Pediatr Gastroenterol Nutr. 1997;24:544-547. (Pubitemid 27216871)
28. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000;15: 1356-1361. (Pubitemid 32052906)
29. McCaughan GW. Asian perspectives on viral hepatitis: Hepatitis C virus infection. J Gastroenterol Hepatol. 2000;15:G90-G93.
30. Forrest CB, Lemke KW, Bodycombe DP, et al. Medication, diagnostic, and cost information as predictors of high-risk patients in need of care management. Am J Manag Care. 2009;15:41-48.
31. Quan HD, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139. (Pubitemid 41587600)
32. Duan N. Smearing estimate-a nonparametric retransformation method. J Am Stat Assoc. 1983;78:605-610.
33. Powers CA, Meyer CM, Roebuck MC, et al. Predictive modeling of total healthcare costs using pharmacy claims data-a comparison of alternative econometric cost modeling techniques. Med Care. 2005;43:1065-1072. (Pubitemid 41587591)
34. Bertsimas D, Bjarnadottir MV, Kane MA, et al. Algorithmic Prediction of Health-Care Costs. Oper Res. 2008;56:1382-1392.
35. Pietz K, Ashton CM, McDonell M, et al. Predicting healthcare costs in a population of veterans affairs beneficiaries using diagnosis-based risk adjustment and self-reported health status. Med Care. 2004;42: 1027-1035. (Pubitemid 39530799)
36. Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care. 2006;12:110-117. (Pubitemid 43256446)
37. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-864. (Pubitemid 33000813)
38. Sales AE, Liu CF, Sloan KL, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Med Care. 2003;41:753-760.
39. Polinski JM, Schneeweiss S, Levin R, et al. Completeness of retail pharmacy claims data: implications for pharmacoepidemiologic studies and pharmacy practice in elderly patients. Clin Ther. 2009;31:2048-2059.
40. Zhao Y, Ellis RP, Ash AS, et al. Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv Res. 2001;36:180-193.
41. Sylvia ML, Griswold M, Dunbar L, et al. Guided care: cost and utilization outcomes in a pilot study. Dis Manage. 2008;11:29-36. (Pubitemid 351271559)
42. Ash AS, Zhao Y, Ellis RP, et al. Finding future high-cost cases: comparing prior cost versus diagnosis-based methods. Health Serv Res. 2001;36:194-206.
43. Hsu J, Huang J, Fung V, et al. Distributing $800 Billion: an early assessment of medicare Part D risk adjustment. Health Affairs. 2009;28: 215-225.
44. Robst J, Levy JM, Ingber MJ. Diagnosis-based risk adjustment for medicare prescription drug plan payments. Health Care Finan Rev. 2007;28:15-30. (Pubitemid 47173624)
45. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24: 465-488. (Pubitemid 40461909)
46. Basu A, Manning WG, Mullahy J. Comparing alternative models: log vs Cox proportional hazard? Health Econ. 2004;13:749-765. (Pubitemid 39136901)
47. Lamers LM, van Vliet R. The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. Health Policy. 2004;68:113-121. (Pubitemid 38373615)
48. Rosen AK, Wang F, Montez ME, et al. Identifying future highhealthcare users-exploring the value of diagnostic and prior utilization information. Disease Management & Health Outcomes. 2005;13: 117-127. (Pubitemid 40522608)
49. Sylvia ML, Shadmi E, Hsiao CJ, et al. Clinical features of high-risk older persons identified by predictive modeling. Dis Manage. 2006; 9:56-62.